Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01024244
Registration number
NCT01024244
Ethics application status
Date submitted
1/12/2009
Date registered
2/12/2009
Date last updated
2/12/2011
Titles & IDs
Public title
A Study of LY2599506 in Patients With Type 2 Diabetes
Query!
Scientific title
A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin
Query!
Secondary ID [1]
0
0
I2Q-MC-GMAH
Query!
Secondary ID [2]
0
0
12781
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - LY2599506
Placebo Comparator: 0 milligrams (mg) Placebo - Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
Experimental: 100 mg LY2599506 - Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
Experimental: 200 mg LY2599506 - Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
Experimental: 400 mg LY2599506 - Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
Experimental: 200 mg LY2599506 once daily - Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
Treatment: Drugs: Placebo
Administered po BID, prior to morning and evening meals for 12 weeks.
Treatment: Drugs: LY2599506
Administered po for 12 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks
Query!
Assessment method [1]
0
0
Change in HbA1c from baseline following 12 weeks of therapy (HbA1c at week 12 minus HbA1c at baseline). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [1]
0
0
Baseline, 12 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in the QT Interval in Electrocardiogram (ECG) at 12 Weeks and 16 Weeks
Query!
Assessment method [1]
0
0
Measures the QT interval in the ECG. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
Query!
Timepoint [1]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [2]
0
0
Change From Baseline in the Homeostasis Model Assessment (HOMA2) Pancreatic Beta Cell Function (%B) at 12 Weeks and 16 Weeks
Query!
Assessment method [2]
0
0
HOMA2 is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state pancreatic beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not calculated or analyzed.
Query!
Timepoint [2]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline in the Homeostasis Model Assessment (HOMA2) of Insulin Sensitivity (%S) at 12 Weeks and 16 Weeks
Query!
Assessment method [3]
0
0
HOMA2 is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population was set at 100%. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not calculated or analyzed.
Query!
Timepoint [3]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [4]
0
0
Change From Baseline in Triglycerides, Low-density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, Total Cholesterol, and Free Fatty Acids at 12 Weeks and 16 Weeks
Query!
Assessment method [4]
0
0
Fasting lipids were measured after an overnight fast. Lipids measured included triglycerides, HDL-C, LDL-C, non-HDL-C, total cholesterol, and free fatty acids. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [4]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [5]
0
0
Change From Baseline in the European Quality of Life -5 Dimension (EQ-5D) at 12 Weeks and 16 Weeks
Query!
Assessment method [5]
0
0
Assesses 5 health domains: mobility, self-care, usual activity, pain, and anxiety/depression with 3 options each. Total scores range from 5 (no problem) to 15 (more severe or frequent problems). An algorithm maps the 5 domain outcomes to a single index (0-1). A higher score indicates better perceived health state. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
Query!
Timepoint [5]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [6]
0
0
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 12 Weeks and 16 Weeks
Query!
Assessment method [6]
0
0
Change in SBP and DBP following 12 weeks of therapy (Week 12 SBP minus SBP at baseline; Week 12 DBP minus DBP at baseline) and 16 weeks of therapy (Week 16 SBPB minus SBP at baseline; Week 16 DBP minus DBP at baseline). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [6]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [7]
0
0
Number of Hypoglycemic Episodes During 12-Week Treatment Period and 4-week Follow-up Period
Query!
Assessment method [7]
0
0
Hypoglycemia was defined as any time a participant feels s/he was experiencing a sign or symptom associated with hypoglycemia or had a blood glucose <70 mg/dL (3.9 mmol/L) even if it was not associated with signs or symptoms of hypoglycemia. Study GMAH was terminated after enrolling only 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [7]
0
0
Baseline through 16 weeks
Query!
Secondary outcome [8]
0
0
Change From Baseline in Body Weight at 12 Weeks and 16 Weeks
Query!
Assessment method [8]
0
0
Weight was measured in the fasting state (with the exception of Visit 1) and after emptying the bladder. Participants were instructed to be lightly clothed and without shoes. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [8]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [9]
0
0
Change From Baseline in the Seven-Point Self-Monitored Blood Glucose (7-point SMBG) at 4 Weeks, 12 Weeks, and 16 Weeks
Query!
Assessment method [9]
0
0
SMBG levels were measured at the following 7 timepoints during the day: fasting pre-breakfast, 2 hours post-breakfast, prior to lunch, 2 hours post-lunch, prior to dinner, 2 hours postdinner, and prior to bed. Study GMAH was terminated after enrolling only 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [9]
0
0
Baseline, 4 weeks, 12 weeks, 16 weeks
Query!
Secondary outcome [10]
0
0
Percentage of Participants Requiring Dose Adjustments During the 12-week Treatment Period
Query!
Assessment method [10]
0
0
Percentage of participants who required dose adjustments at the discretion of the investigator for participants with persistent blood glucose<70 milligrams per deciliter (mg/dL). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
Query!
Timepoint [10]
0
0
Baseline through 12 weeks
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Lipase and Amylase Measurements Above 2-fold Upper Limits of Normal (ULN) During the 12-week Treatment Period
Query!
Assessment method [11]
0
0
Lipase and amylase concentrations were assessed. Amylase normal limits for males and females are 28-100 units per liter (U/L) (18-50 years), 28-120 U/L (50-60 years), and 28-150 U/L (60-70 years). Normal lipase limits for males and females are 0-100 U/L (18-50 years; 50-60 years) and 0-120 U/L (60-70 years). Study GMAH was terminated after enrolling only 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [11]
0
0
Baseline through 12 weeks
Query!
Secondary outcome [12]
0
0
Percentage of Participants With Clinically-Significant Elevations of Alanine Aminotransferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT) During the 12-week Treatment Period and 4-week Follow-up Period
Query!
Assessment method [12]
0
0
Clinically significant elevations of ALT/SGPT were considered =3 times the upper limit of normal (ULN). The percentage of participants above 2- and 5-fold ULN was not analyzed due to the early termination of the trial. The percentage of participants with ALT 3-fold ULN or higher is presented.
Query!
Timepoint [12]
0
0
Baseline through 12 weeks, Baseline through 16 weeks
Query!
Secondary outcome [13]
0
0
Change From Baseline in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 12 Weeks and 16 Weeks
Query!
Assessment method [13]
0
0
DTSQ, an 8-item questionnaire, measures satisfaction with treatment, perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia. Response options range from 6 (best case) to 0 (worst case). Total scores for treatment satisfaction range from 0-36. Higher scores indicate higher satisfaction. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
Query!
Timepoint [13]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [14]
0
0
Change From Baseline in the Adult Low Blood Sugar Survey (LBSS-33 Item Scale) at 12 Weeks and 16 Weeks
Query!
Assessment method [14]
0
0
Assesses 2 hypoglycemia domains, with each item score from 0 (never engages in behavior) to 4 (always engages in behavior): Behavioral (15 items; range 0-60) and Worry about hypoglycemia (18 items; range 0-72). Total score is the sum of both domains (range 0-132). Higher scores indicate greater negative impact. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall, and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading. As a result, this outcome measure was not analyzed.
Query!
Timepoint [14]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [15]
0
0
Changes From Baseline in the Diabetes Symptoms Checklist-Revised (DSC-R) at 12 Weeks and 16 Weeks
Query!
Assessment method [15]
0
0
Comprise 6 subscales (34 items). Each item score: 1 (not troublesome) to 5 (extremely troublesome) and transformed to 0-4 scale. Subscale score=sum of item scale in each subscale/total number of items. Global score=sum of scores by dimension. All scores standardized (0-100). Higher scores=greater symptom burden. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
Query!
Timepoint [15]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Secondary outcome [16]
0
0
Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period
Query!
Assessment method [16]
0
0
The average total daily dose (sum of assigned morning and afternoon doses), in milligrams (mg), at each visit. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [16]
0
0
Baseline through 12 weeks
Query!
Secondary outcome [17]
0
0
Maximum Plasma Concentration (Cmax) at the Steady State for LY2599506
Query!
Assessment method [17]
0
0
The Cmax value measures the maximum plasma concentration at steady state following administration of doses of LY2599506. Due to the nature of the sparse sampling approach, Cmax was estimated using the posthoc pharmacokinetic (PK) parameters obtained from population PK (PopPK) modeling. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [17]
0
0
Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12
Query!
Secondary outcome [18]
0
0
Area Under the Concentration-time Curve (AUC) at a Dosing Interval (AUCtau) at the Steady State for LY2599506
Query!
Assessment method [18]
0
0
The AUCtau values measure the area under the plasma concentration time curve at a dosing interval at steady state for LY2599506. Due to the nature of sparse sampling approach taken for the study AUC tau was estimated using the posthoc pharmacokinetic (PK) parameters obtained from population PK (PopPK) modeling. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
Query!
Timepoint [18]
0
0
Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12
Query!
Secondary outcome [19]
0
0
30-day Adjusted Rates of Self-reported Hypoglycemic Episodes Overall
Query!
Assessment method [19]
0
0
Hypoglycemia: any time a participant experienced a sign/symptom associated with hypoglycemia or had blood glucose <70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). The 30-day adjusted rate=(total number of episodes between 2 time intervals/number of days between intervals) X 30 days. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [19]
0
0
Baseline through 16 weeks
Query!
Secondary outcome [20]
0
0
Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks
Query!
Assessment method [20]
0
0
Heart rate was measured in heartbeats per minute. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Query!
Timepoint [20]
0
0
Baseline, 12 weeks, 16 weeks
Query!
Eligibility
Key inclusion criteria
- Have type 2 diabetes mellitus prior to entering the trial.
- Are currently being treated with diet and exercise therapy consistent with the local
standards of medical care.
- May be treated with diet and exercise alone or in combination with a stable of
metformin for at least 3 month before entering the trial.
- Have a hemoglobin A1c value between 7.0% and 10.0 %, inclusive.
- Are women not of child-bearing potential due to surgical sterilization (hysterectomy
or bilateral oophorectomy or tubal ligation) or menopause. Male patients will be
advised to use a reliable method of birth control during the study and until 3 months
after the last dose of study medication if their partner is of child-bearing
potential.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Use of insulin or any antidiabetic agent other than metformin during the 3 months
prior entering the trial.
- Have a gastrointestinal disease that significantly impacts gastric emptying or
motility (for example, severe gastroparesis or pyloric stenosis), in the opinion of
the investigator, or have undergone gastric bypass or gastric banding surgery.
- Have had more than 1 episode of severe hypoglycemia within 6 months prior to entry
into the study, or are currently diagnosed as having hypoglycemia unawareness.
- Have had 2 or more emergency room visits or hospitalizations due to poor glucose
control in the past 6 months.
- Have cardiac autonomic neuropathy (for example, resting tachycardia or orthostatic
hypotension), based on clinical signs, symptoms, or appropriate diagnostic testing.
- Have cardiac disease with functional status that is New York Heart Association Class
II, III or IV or a history of myocardial infarction, unstable angina, or decompensated
congestive heart failure in the past 6 month.
- Have poorly controlled hypertension (that is, mean systolic blood pressure of greater
or equal than 160 mm Hg or mean diastolic blood pressure of greater or equal than 100
mm Hg) history of malignant hypertension, evidence of renal artery stenosis and/or
evidence of labile blood pressure including symptomatic postural hypotension. Doses of
antihypertensive medications must be stable for 30 days before randomization.
- Have fed or fasting state hypertriglyceridemia (defined as >6.8 millimoles per liter
[mmol/L], 600 milligrams per deciliter [mg/dl]) at screening. If taking lipid-lowering
agents, doses of these medications must be stable for 30 days prior to randomization.
- Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis,
or repeated alanine transaminase (ALT) levels >2.5 times the upper limit of the
reference range at screening.
- Have evidence of a significant active, uncontrolled endocrine or autoimmune
abnormality, as judged by the Investigator at screening.
- Have an active or untreated malignancy or have been in remission from a clinically
significant malignancy (other than basal or squamous cell skin cancer, in situ
carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
- Have a history of seizure disorder.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
78
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - St. Leonards
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Daw Park
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Query!
Recruitment postcode(s) [1]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [2]
0
0
5041 - Daw Park
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Kansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
New Jersey
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
Puerto Rico
Query!
State/province [4]
0
0
Manati
Query!
Country [5]
0
0
Puerto Rico
Query!
State/province [5]
0
0
San Juan
Query!
Country [6]
0
0
Russian Federation
Query!
State/province [6]
0
0
Arkhangelsk
Query!
Country [7]
0
0
Russian Federation
Query!
State/province [7]
0
0
Moscow
Query!
Country [8]
0
0
Russian Federation
Query!
State/province [8]
0
0
Rostov-On-Don
Query!
Country [9]
0
0
Russian Federation
Query!
State/province [9]
0
0
Saint Petersburg
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Alcira
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Alicante
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Dos Hermanas
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Santa Cruz De Tenerife
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to help answer the following questions:
- To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo
for 12 weeks.
- To evaluate the safety of LY2599506 in participants with diabetes.
- To determine if LY2599506 has the ability to control blood sugar in participants with
diabetes.
- To determine how much LY2599506 should be given to participants.
- To determine if LY2599506 has an effect on a participant's weight.
The study design consists of 4 study periods: a screening period, a 4-week dose adjustment
period, an 8-week treatment period, and a 4-week follow-up period.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01024244
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01024244
Download to PDF